Status:
COMPLETED
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tu...
Eligibility Criteria
Inclusion
- Histologically confirmed malignant solid tumor that has progressed following standard therapy, or for which no standard effective treatment is available
- Tumor expression of Lewis Y antigen ( \> or = 20% tumor cells positive for Lewis Y by immunohistochemistry assay)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion
- Chemotherapy, radiation therapy, other cancer therapy, or investigational agents within 21 days of the first dose of CMD-193 (42 days if the previous chemotherapy included nitrosoureas or mitomycin C)
- Symptomatic or clinically active CNS metastases. Subjects who have had prior treatment with radiotherapy or surgical resection for CNS metastases will be permitted if CNS metastases have remained stable and have not required any treatment for at least 3 months prior to the first dose of CMD-193.
- Significant prior allergic reaction to recombinant human or murine proteins
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00161642
Start Date
November 1 2004
End Date
July 1 2007
Last Update
September 10 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Lebanon, New Hampshire, United States, 03756
2
Philadelphia, Pennsylvania, United States, 19111
3
Nashville, Tennessee, United States, 37203